{"id":"NCT03896581","sponsor":"UCB Biopharma SRL","briefTitle":"A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","officialTitle":"A Multicenter, Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-03-28","primaryCompletion":"2021-12-08","completion":"2022-02-14","firstPosted":"2019-04-01","resultsPosted":"2024-10-16","lastUpdate":"2025-06-22"},"enrollment":400,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"Bimekizumab","otherNames":["BKZ","UCB4940"]},{"type":"OTHER","name":"Placebo","otherNames":["PBO"]}],"arms":[{"label":"Bimekizumab dosage regimen","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This is a study to demonstrate the clinical efficacy, safety and tolerability of bimekizumab administered subcutaneously (sc) compared with placebo in the treatment of tumor necrosis factor alpha-inadequate responders (TNFÎ±-IR) subjects with active Psoriatic Arthritis (PsA).","primaryOutcome":{"measure":"Percentage of Participants With American College of Rheumatology 50 (ACR50) Response","timeFrame":"From Baseline to Week 16","effectByArm":[{"arm":"Placebo","deltaMin":6.8,"sd":null},{"arm":"Bimekizumab 160mg","deltaMin":43.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":10},"locations":{"siteCount":92,"countries":["United States","Australia","Canada","Czechia","Germany","Hungary","Italy","Japan","Poland","Russia","United Kingdom"]},"refs":{"pmids":["38446397","38488975","39120849","39534481","40347389","40194794","39892885","39313302","39215949","39120848","38754125","38073049","36495881"],"seeAlso":["https://www.ema.europa.eu/en/documents/product-information/bimzelx-epar-product-information_en.pdf","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":132},"commonTop":["Corona virus infection","Nasopharyngitis","Upper respiratory tract infection","Urinary tract infection","Oral candidiasis"]}}